Icon

COSELA (nda214200)- (EQ 300MG BASE/VIAL)

TRILACICLIB DIHYDROCHLORIDE PHARMACOSMOS
EQ 300MG BASE/VIAL
No No
2039-Jul-23 2026-Feb-12
None None
None No
COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
0 0 0
Total Other Developers 5
Drugs with Suitability No
EQ 300MG BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.